Antibodies targeting programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have achieved early success in clinical trials, inducing durable remission in various tumor types (4–6). Here, PDCD1 is linked to neoplasm.